Neoplasms

Heart and Blood Diseases

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Symptoms and General Pathology

Wounds and Injuries

Rare Diseases

Multiple Myeloma

Neoplasms, Plasma Cell

Neoplasm Metastasis

Lymphoma

Fractures, Bone

Femoral Fractures

Sarcoma

Osteosarcoma

Fractures, Spontaneous

Neoplasms, Connective and Soft Tissue

Neoplasms by Histologic Type

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Paraproteinemias

Blood Protein Disorders

Hematologic Diseases

Hemorrhagic Disorders

Lymphoproliferative Disorders

Immunoproliferative Disorders

Leg Injuries

Neoplastic Processes

Lymphosarcoma

Soft Tissue Sarcoma

Fibrinolytic Agents

Anticoagulants

All Drugs and Chemicals

Heparin, Low-Molecular-Weight

Tinzaparin

Dalteparin

Heparin

Calcium heparin

Participants receive dalteparin SC QD starting 12-24 hours after surgery on post-operative day 1 until hospital discharge, about 7-10 days.

Patrick Lin

This trial studies how well dalteparin works in preventing deep vein thrombosis (DVT) (blood clots) in participants with cancer. Dalteparin is a blood thinner that can treat blood clots and may prevent them from forming.

PRIMARY OBJECTIVES:

I. To determine the safety of dalteparin as prophylaxis against deep venous thrombosis (DVT) in orthopedic oncology patients.

II. To determine whether there are significantly increased bleeding complications at the surgical site after major oncologic operations in the lower extremity.

OUTLINE:

Participants receive dalteparin subcutaneously (SC) once daily (QD) starting 12-24 hours after surgery on post-operative day 1 until hospital discharge, about 7-10 days.

Dalteparin in Preventing DVT in Participants With Cancer

DVT Prophylaxis in Orthopaedic Oncology Patients - A Safety Study

Our primary outcome was the incidence of post-surgical complications, to include wound dehiscence, infection, and seroma.

A secondary outcome was the occurrence of venous thrombolembolism in the post-operative period, to include both deep venous thrombosis in the lower extremity as well as pulmonary embolism.

The volume of packed red blood cell transfusion in the post-operative period

National Cancer Institute (NCI)

M.D. Anderson Cancer Center

Received dalteparin 5000 units daily postop, patients with metastatic disease.

Interventional (Dalteparin, Metastatic)

Received dalteparin 5000 units daily postop, patients with primary sarcomas.

Interventional (Dalteparin, Sarcoma)

Total

Age, Categorical

Sex: Female, Male

Ethnicity (NIH/OMB)

Race (NIH/OMB)

United States

Region of Enrollment

Femur/Thigh

Tibia/Calf

Popliteal

Tumor Location

Carcinoma

Tumor Type

Wide Excision Only

Segmental Reconstruction

Curettage, Internal Fixation

Surgery

Patrick Lin, MD/Professor, Orthopaedic Oncology

Seroma

Wound Infection

Wound Dehiscence

Number of Participants With Post-operative Wound Complications

Deep venous thrombosis

Pulmonary embolism

Number of Participants With Occurrence of Venous Thromboembolism

Post-Operative Blood Transfusion

Overall Study

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Dalteparin in Preventing DVT in Participants With Cancer	NCT00525057	Bone Sarcoma Femur Fracture Lymphoma Metastatic Neop... Pathologic Frac... Plasma Cell Mye... Soft Tissue Sar...	Dalteparin	30 Years -	M.D. Anderson Cancer Center
Dalteparin in Preventing DVT in Participants With Cancer	NCT00525057	Bone Sarcoma Femur Fracture Lymphoma Metastatic Neop... Pathologic Frac... Plasma Cell Mye... Soft Tissue Sar...	Dalteparin	30 Years -	M.D. Anderson Cancer Center

Spots Global Cancer Trial Database for femur fracture